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GMP-compliant radiosynthesis of [18F]altanserin and human
plasma metabolite studies
Abstract
[(18)F]altanserin is the preferred radiotracer for in-vivo labeling of serotonin 2A receptors by positron
emission tomography (PET). We report a modified synthesis procedure suited for reliable production of
multi-GBq amounts of [(18)F]altanserin useful for application in humans. We introduced thermal
heating for drying of [(18)F]fluoride as well as for the reaction instead of microwave heating. We
furthermore describe solid phase extraction and HPLC procedures for quantitative determination of
[(18)F]altanserin and metabolites in plasma. The time course of arterial plasma activity with and without
metabolite correction was determined. 90 min after bolus injection, 38.4% of total plasma activity
derived from unchanged [(18)F]altanserin. Statistical comparison of kinetic profiles of [(18)F]altanserin
metabolism in plasma samples collected in the course of two ongoing studies employing placebo, the
serotonin releaser dexfenfluramine and the hallucinogen psilocybin, revealed the same tracer
metabolism. We conclude that metabolite analysis for correction of individual plasma input functions
used in tracer modeling is not necessary for [(18)F]altanserin studies involving psilocybin or
dexfenfluramine treatment.
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Abstract 
[18F]altanserin is the preferred radiotracer for in-vivo labelling of serotonin 2A receptors by Positron 
Emission Tomography (PET). We report a modified synthesis procedure suited for reliable production 
of multi-GBq amounts of [18F]-altanserin useful for application in humans. We introduced thermal 
heating for drying of [18F]-fluoride as well as for the reaction instead of microwave heating. We 
furthermore describe solid phase extraction and HPLC procedures for quantitative determination of 
[18F]-altanserin and metabolites in plasma. The time course of arterial plasma activity with and without 
metabolite correction was determined. 90 min after bolus injection, 38.4% of total plasma activity 
derived from unchanged [18F]altanserin. Statistical comparison of kinetic profiles of [18F]altanserin 
metabolism in plasma samples collected in the course of two ongoing studies employing placebo, the 
serotonin releaser dexfenfluramine and the hallucinogen psilocybin, revealed the same tracer 
metabolism. We conclude that metabolite analysis for correction of individual plasma input functions 
used in tracer modelling is not necessary for [18F]altanserin studies involving psilocybin or 
dexfenfluramine treatment. 
Keywords: [18F]altanserin, PET, positron emission tomography, radiosynthesis, metabolite analysis, 
GMP,  human study 
 
1. Introduction 
The serotonin (5-HT) 2A receptor antagonist [18F]altanserin has traditionally been preferred over other 
labelling compounds for positron emission tomographic (PET) mapping of 5-HT2A receptor distribution 
in vivo. We herein report a fully automated synthesis procedure with good yields and reproducibility 
suited for reliable production of GBq amounts of [18F]-altanserin with radiochemical purity > 98%. The 
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synthesis protocol and quality control methods have been constructed in view of “Good Manufacturing 
Practise” (GMP) demands suited for clinical use in human subjects. We introduced thermal heating for 
the radiochemical synthesis instead of microwave heating and separated [18F]-altanserin from the raw 
synthesis product in the preparative High Pressure Liquid Chromatography (HPLC) eluate by  C-18 
solide phase extraction (SPE). A novel, efficient SPE technique and an optimized HPLC procedure for 
quantitative determination of [18F]-altanserin and its metabolites in human plasma samples up to 90 
min post bolus tracer-injection is presented. Determination of parent tracer/active metabolite ratio is 
important for correction of the arterial input function used for kinetic tracer modelling, since [18F]-
altanserin radiometabolites have been shown to pass the blood-brain barrier [Price et al., 2001a; Price 
et al., 2001b]. Recoveries from radiometabolite solid phase extraction and the kinetics of [18F]-
altanserin metabolism in humans were also determined. 
 
2. Experimental  
2.1 General  
Radiosynthesis of [18F]-altanserin and quality control procedures were done according to GMP 
guidelines. All solvents and standard chemicals were of analytical degree and purchased from Fluka 
(Buchs, Switzerland) and Merck (Darmstadt, Germany). Altanserin standard, the synthesis precursor 
nitroaltanserin, Kryptofix K222 as well as pre-conditioned Sep-Pak Light QMA cartridges for F-- trapping 
were obtained from ABX (Radeberg, Germany). Sep-Pak Plus C-18 solid phase extraction (SPE) 
cartridges were produced by Waters (Milford-MA, USA). For semi-preparative purification of the 
reaction mixture, we used a Merck Hitachi L-6000A HPLC pump, a Merck Hitachi L-4000A UV 
detector and a Veenstra Instruments VRM 202 radioactivity detector. 
 
2.2 Radiochemistry 
[18F]Fluoride was produced via the 18O(p, n)18F nuclear reaction in 1,5 mL of 98% enriched [18O]-water 
in a silver target. Upon end of cyclotron irradiation, the no-carrier-added aqueous [18F]fluoride solution 
was directed online into the synthesis unit and trapped on a pre-conditioned QMA cartridge. 
Desorption of [18F]fluoride from the QMA cartridge and transfer into a 10 mL reaction vial was 
achieved by elution with a mixture of 10 mg Kryptofix K222 in 1 mL acetonitrile and 2-3 mg K2CO3 in 0.5 
mL water. The aqueous 18F- solution was concentrated to dryness at 130 °C under a stream of 
nitrogen for 10 - 15 min. The residue was dissolved in anhydrous acetonitril (1.5 mL), and the solvent 
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evaporated to dryness at 130 °C under a stream of nitrogen. This procedure of azeotropic distillation 
was repeated twice. Drying of the 18F-/Kryptofix K222 solution was completed by increase of 
temperature to 150 °C kept for two minutes.  
0.9 mL anhydrous dimethylsulfoxide containing 4 to 5 mg nitroaltanserin was added to the 
exhaustively dried 18F-/Kryptofix K222 residue. Under continuous stirring, the reaction solution was kept 
at 150 °C for 9 min. After cooling of the reaction vessel to 40 °C, the reaction mixture was diluted with 
3 mL of mobile phase used for HPLC, consisting of sodium acetate solution 0.08M, adjusted to pH 5 
by addition of conc. acetic acid (87.7 %, v/v), ethanol (4.1 %) and tetrahydrofuran (8.2 %). Hereafter 
the diluted reaction solution was completely transferred into a 5 mL HPLC loop and the [18F]altanserin 
raw product separated by semipreparative HPLC. Chromatographic separation of [18F]altanserin from 
precursor and synthesis-byproducts was achieved by use of a VP 125/10 Nucleosil 100-7 C18 
semipreparative column (Macherey-Nagel), protected by a 5 cm guard column of identical stationary 
phase. The flow rate of mobile phase was 9 mL/min and the UV detection wavelength was 254 nm. 
The middle segment of the [18F]altanserin peak (as determined by use of the radioactivity detector) 
was collected in a dilution bottle containing 70 mL of water. The thoroughly mixed content of the 
dilution bottle was then slowly passed through a Waters C-18 SepPak Light cartridge pre-conditioned 
with 10 mL ethanol and 10 mL water. After drying under a stream of nitrogen for 5 min, the extraction 
column was washed with 17 mL water, dryed anew and the [18F]altanserin eluted with 1.5 mL ethanol 
trough a SF-Millex-FG 0.22 µM sterile filter into the sterile product bottle containing 14.5 mL of sterile 
saline solution 0.9%. Immediately after elution of the product into the collection bottle, total activity was 
measured in a gamma counter chamber (Veenstra Instruments VDC-405).  
 
2.3 Analytical HPLC and quality control 
The HPLC equipment used for determination of chemical and radiochemical purity of the final 
injectable [18F]altanserin product formulation consisted of a LaChrom 7000 HPLC system (pump L-
7100, autosampler L-7200, interface D-7000) controlled by D-7000 HSM version 2 for Windows NT 
software, a Bioscan flow-count B-FC-3200 NaI scintillation detector and a LaChrom L-7400 UV 
detector operated at a detection wavelength of 293 nm (a local maximum of UV-absorbance of 
altanserin and nitroaltanserin). The HPLC system was operated at an ambient temperature of 20-25 
ºC. Chromatographic separation of was achieved on a CC125/3 Nucleosil 100-10 C-18 analytical 
column from Macherey Nagel. As mobile phase we used  tetrahydrofuran (35.0 %) and an aqueous 
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sodium acetate solution 0.08M adjusted to pH 5 by addition of conc. acetic acid (65.0 %, v/v). The flow 
rate was 1 mL/min, and the standard injection volume was 15 µL.  
pH value, identity of [18F]altanserin, chemical and radiochemical purity, amount of altanserin and 
synthesis precursor (by HPLC) as well as residual solvent content in the product preparation (by gas 
chromatography, GC) were checked after the end of each synthesis. Product sterility and absence of 
endotoxins were later determined in the retained samples. Identity and purity of 18F radionuclide was 
confirmed periodically. 
 
2.4 Radiometabolite analysis 
Heparinized arterial blood samples (5 mL) collected 1, 1.5, 5, 15, 30, 45, 60 and 90 min after bolus 
injection of 250 MBq [18F]altanserin (30 s bolus) were centrifuged at – 5°C by use of a Heraeus 
Varifuge RF centrifuge (10’000 g, 5 min). The resulting plasma supernatant of each sample was 
transferred into test tubes containing 5 mL of acetic acid 50 mM spiked with 2 µMol (non labelled, 
“cold”) altanserin. After vortexing for 2 min, diluted plasma samples were slowly passed through 
Waters C-18 SepPak Light cartridges pre-conditioned with 10 mL ethanol and 10 mL water. After 
drying under a stream of nitrogen for 1 min, the extraction columns were washed with 20 mL water, 
dried anew and the parent tracer and metabolites eluted into HPLC vials with 1.5 mL methanol. For 
determination of tracer- and metabolite recovery (“activity balance”), total activity of original plasma 
samples, washing solutions and eluates were determined by use of a Packard COBRA II auto-gamma 
counter. 
The isocratic HPLC method used for quality control purposes (see 2.3 “Analytical HPLC”) was used 
also for chromatographic separation of parent tracer and active [18F]altanserin metabolites. Injection 
volume was 400 µL. For each sample, two fractions of eluate were collected in test tubes: fraction 1 
(containing all active altanserin metabolites) was collected from t0 (time of injection) to the onset of the 
altanserin UV-peak (arising from sample spiking) and fraction 2 (containing authentic tracer) was 
collected from the onset of altanserin peak to t0 + 6 min. Radioactivity in the fractionated HPLC eluates 
was quantitatively determined in the gamma counter. 
 
3. Results and discussion 
3.1 Synthesis and quality control 
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Specifications of [18F]altanserin synthesis reported as average values from the 20 most recent 
productions are summarized in Table 1. Average synthesis time was 114 ± 4 min and the 
radiochemical yield at end of synthesis (EOS) was 13 ± 2%. Multi-GBq amounts of [18F]altanserin of 
radiochemical purity ≥ 98% suited for application to human subjects were produced with high 
reliability. The chromatographic separation profile of the synthesis raw product using preparative 
reversed-phase HPLC is shown in Figure 1. [18F]altanserin eluting with a retention time of 50 min is 
fully baseline-separated from the precursor nitroaltanserin. The following specifications of the 
analytical HPLC method used for quality control of the [18F]altanserin injection solution were 
determined: Interassay method precision for altanserin (5 measurements over an interval of 4 months) 
was 8.8 ± 1.9 % and intraassay method precision was 4.2 ± 4.3 %. Correlation coefficients r2 for linear 
regression (UV and radioactivity detection) were > 0.99 for both altanserin and the precursor 
nitroaltanserin. Stability of [18F]altanserin was determined for a shelf-life of four hours after end of 
synthesis by HPLC monitoring. Within that period, [18F]altanserin peak areas were stable (SD ±3 %) 
and no additional peaks appeared in the chromatograms. 
Previously published synthesis procedures involved microwave heating [Lemaire et al., 1991; Monclus 
et al., 1998; Tan et al., 1999] or thermal heating in an electrochemical cell [Hamacher and Coenen, 
2006]. Chemical yields using these procedures are reported to be higher (20 – 25%), but automation 
of microwave heating is considered technically complicated [Lemaire et al., 1991]. We see the use of 
conventional thermal heating using a thermostat-regulated heating lamp as a technically simple and 
easily implementable alternative for routine production of [18F]altanserin. According to our experience, 
exhaustive azeotropic distillation in order to ensure complete absence of water in the reaction vessel is 
the most critical point for successful production of [18F]altanserin.  
 
3.2 Metabolite analysis and metabolite corrected [18F]altanserin time-activity curve 
Blood to plasma radioactivity ratio determined in human blood samples collected between 1 und 90 
min after bolus injection of 250 MBq [18F]altanserin was 0.72 ± 0.01 (N = 16). During this period, blood 
to plasma ratio remained unchanged despite the appearance of metabolites in the blood stream. Our 
findings confirm earlier data provided by Biver et al. [Biver et al., 1994]. Table 2 shows recovery rates 
from radiometabolite solid phase extractions (mean ± SD, N=6). Summing up data from 4 different 
sampling times (1, 5, 30 and 60 min. following start of bolus tracer injection), > 97.8 % of total plasma 
radioactivity is retained on solid phase cartridge during sample passage, < 0.2 % of activity is lost due 
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to washing of the cartridge, and 4.7 ± 2.6 % of total activity remains on cartridge after metabolite 
elution with methanol. 93.7 ± 2.6 % of total radioactivity in the arterial plasma samples is eluted into 
the vials and available for metabolite separation by HPLC. Mean overall recovery for all 4 samples is 
100.1 ± 1.4 %. Metabolism of [18F]altanserin as percentage of radioactivity in arterial plasma samples 
deriving from authentic tracer over time is shown in Figure 2. The graph is based on arterial plasma 
data from 16 healthy subjects receiving 30 second bolus injections of 250 MBq [18F]altanserin (mean ± 
SD). Within 90 minutes after tracer injection, 61.6 ± 4.9 % of the original amount of parent drug is 
metabolized.  
In two currently ongoing human studies at our PET facility, we use [18F]altanserin a) for measuring the 
occupancy of 5-HT2A receptors by the classic tryptamine hallucinogen psilocybin and its relation to 
subjectively experienced alterations in cognition, perception and mood, and b) investigating the 
serotonergic neurotransmission in MDMA (“Ecstasy”) users and drug-naïve controls employing a 
serotonin challenge with the 5-HT releaser dexfenfluramine. From these studies we obtained arterial 
plasma samples (from healthy male subjects; age 24.6 ± 4.1 years) out of three different experimental 
conditions – following medication with placebo (PLA, N=20), psilocybin (PY, 250µg/kg body weight; 
administered 70 min prior to PET scan; N=7), and dexfenfluramine (DEX, 40-60 mg; administered 120 
min before tracer application; N=13). Metabolite analysis provided individual kinetic profiles of 
[18F]altanserin degradation (% radioactivity deriving from parent tracer vs. time curves) for each study 
subject. A standard two-factorial ANOVA procedure with repeated measurement was used for 
statistical analysis. In regard to the three treatment conditions, analysis of variance revealed no 
statistically significant difference for [18F]altanserin metabolism at any sampling time (PLA vs. PY: 
[F(7,42) = 1.88; p = 0.11]; PLA vs. DEX: [F(7,84) = 1.21; p = 0.30]). We therefore conclude that 
[18F]altanserin metabolism is robust and not measurably affected neither by dexfenfluramine nor by 
psilocybin treatment. Hence, although preferable, metabolite analysis for correction of the individual 
plasma input function used in tracer modelling is not necessary for future [18F]altanserin studies 
involving psilocybin or dexfenfluramine treatment.  
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Tables and Figures 
 
 
 
Table 1. Specifications of [18F]altanserin synthesis (mean ± SD from 20 productions)
Parameter Value Parameter Value
Synthesis time 114 ± 4 min Radionuclide purity > 99 % 18F
Radiochemical yield (EOS) 13.2 ± 2.0 % Radiochemical purity 97.8 ± 0.5 %
Aspect clear, colorless liquid; no suspended particles Amount of altanserin 25 ± 5 µg/8 mL
pH value 5.3 ± 0.1 Synthesis precursor < LOD *)
Activity concentration (EOS) 250 ± 58 MBq/mL Residual content of solvents complies with specifications
Specific activity (EOS) 34 ± 7 GBq/µMol Sterility and endotoxins complies with specifications
Radionuclide identity 18F (t1/2 = 109.8 min)
*) Limit of detection of analytical method  
 
 
 
 
 
 
 
 
Table 2. Recoveries from radiometabolite solid phase extraction (mean ± SD, N=6)
Sample # Recovery (%) Sample # Recovery (%)
4 (t0 + 1 min) 13 (t0 + 30 min)
Sample passage (not retained analytes) 1.2 ± 0.5 Sample passage (not retained analytes) 2.5 ± 0.4
Washing solution 0.03 ± 0.01 Washing solution 0.14 ± 0.06
Eluate 95.7 ± 2.5 Eluate 94.1 ± 2.4
Residual activity on cartridge 4.8 ± 2.2 Residual activity on cartridge 4.0 ± 2.7
Overall recovery 100.7 ± 2.9 Overall recovery 100.7 ± 0.5
8 (t0 + 5 min) 15 (t0 + 60 min)
Sample passage (not retained analytes) 1.7 ± 0.2 Sample passage (not retained analytes) 3.2 ± 0.6
Washing solution 0.09 ± 0.05 Washing solution 0.21 ± 0.09
Eluate 92.7 ± 1.8 Eluate 91.2 ± 3.6
Residual activity on cartridge 4.4 ± 2.6 Residual activity on cartridge 5.5 ± 2.9
Overall recovery 99.0 ± 1.7 Overall recovery 100.1 ± 0.6
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Figure 1.  Preparative HPLC profile of [18F]altanserin. Upper graph: UV-detection (254 nm); lower graph:  
 radioactivity detection. Experimental conditions: Stat. phase = VP 125/10 Nucleosil 100-7 C18 
 (Macherey-Nagel); eluent = sodium acetate buffer pH 5 : tetrahydrofuran : ethanol / 87.7 : 8.2 : 4.1; 
 flow rate = 9 mL / min. 
[18F]altanserin 
nitroaltanserin 
(precursor) 
 30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
Time after tracer injection [min]
U
n
m
e
t
a
b
o
l
i
s
e
d
 
[
1
8
F
]
a
l
t
a
n
s
e
r
i
n
 
i
n
 
p
l
a
s
m
a
 
[
%
]
 
 
Figure 2.  Metabolism of [18F]altanserin. Percentage of activity in arterial plasma deriving from 
 authentic tracer vs. time after bolus injection of 250 MBq [18F]-altanserin (mean ± SD) from 
 16 healthy male subjects. 
 
Time [min] Authentic tracer [%]
1 91.7
1.5 90.2
5 79.4
15 65.9
30 54.4
45 47.9
60 43.5
90 38.4
